Dhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Bchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:42447. https://doi.org/10.1182/blood-2016-08-733196.

Article CAS PubMed PubMed Central Google Scholar

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:275367. https://doi.org/10.1182/blood.2021013626.

Article CAS PubMed PubMed Central Google Scholar

Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:127591. https://doi.org/10.1182/blood-2017-09-801498.

Article CAS PubMed PubMed Central Google Scholar

Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2021;56:21824. https://doi.org/10.1038/s41409-020-01005-y.

Article Google Scholar

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:86573. https://doi.org/10.3324/haematol.2016.159343.

Article CAS PubMed PubMed Central Google Scholar

Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:11907. https://doi.org/10.1200/jco.2010.31.8121.

Article PubMed PubMed Central Google Scholar

Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:32936. https://doi.org/10.1200/jco.2015.63.3826.

Article PubMed Google Scholar

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (minimal) residual disease via multiparameter flow cytometry in adult acute myeloid. Leuk Leuk. 2016;30:145664. https://doi.org/10.1038/leu.2016.46.

Article CAS Google Scholar

Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, et al. Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2016;22:66975. https://doi.org/10.1016/j.bbmt.2015.10.024.

Article Google Scholar

Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, et al. Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. 2020;34:17015. https://doi.org/10.1038/s41375-019-0671-x.

Article PubMed Google Scholar

Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers. 2020;12:2339.

Article CAS PubMed PubMed Central Google Scholar

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Soci G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party. Eur Soc Blood Marrow Transplant Am J Hematol. 2018;93:114252. https://doi.org/10.1002/ajh.25211.

Article Google Scholar

Schlenk RF, Dhner K, Mack S, Stoppel M, Kirly F, Gtze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28:46428. https://doi.org/10.1200/jco.2010.28.6856.

Article PubMed Google Scholar

Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:37308. https://doi.org/10.1200/jco.2010.28.8852.

Article PubMed PubMed Central Google Scholar

Le Bourgeois A, Labopin M, Marais A, de Latour RP, Blaise D, Chantepie S, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020;99:185562. https://doi.org/10.1007/s00277-020-04074-7.

Article CAS PubMed Google Scholar

Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, et al. Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2017;23:27884. https://doi.org/10.1016/j.bbmt.2016.11.002.

Article Google Scholar

Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:567587. https://doi.org/10.1200/jco.2005.07.061.

Article PubMed Google Scholar

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, et al. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2016;142:31724. https://doi.org/10.1007/s00432-015-2050-y.

Article CAS PubMed Google Scholar

Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transpl. 2005;35:96570. https://doi.org/10.1038/sj.bmt.1704938.

Article CAS Google Scholar

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:170313. https://doi.org/10.1182/blood-2018-02-829911. e-pub ahead of print 2018/09/08.

Article CAS PubMed Google Scholar

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, et al. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J. 2021;11:80 https://doi.org/10.1038/s41408-021-00471-x.

Article PubMed PubMed Central Google Scholar

Lachowiez CA, Atluri H, DiNardo CD. Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia. Ther Adv Hematol. 2022;13:20406207221093964 https://doi.org/10.1177/20406207221093964.

Article PubMed PubMed Central Google Scholar

Stelljes M, Middeke JM, Bug G, Wagner E-M, Mueller LP, Christoph S, et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140:911. https://doi.org/10.1182/blood-2022-159962.

Article Google Scholar

Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:150716. https://doi.org/10.3324/haematol.2019.243410.

Article CAS PubMed PubMed Central Google Scholar

Bazarbachi A, Labopin M, Battipaglia G, Djabali A, Passweg J, Soci G, et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. Haematologica. 2019;104:e398e401. https://doi.org/10.3324/haematol.2018.211615.

Article CAS PubMed PubMed Central Google Scholar

Abou Dalle I, El Cheikh J, Bazarbachi A. Pharmacologic strategies for post-transplant maintenance in acute myeloid leukemia: it is time to consider! Cancers. 2022; 14. https://doi.org/10.3390/cancers14061490.

Read this article:
Impact of disease burden on clinical outcomes of AML patients ... - Nature.com